Patents by Inventor Andrew John MCKNIGHT

Andrew John MCKNIGHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FN14 ANTIBODIES AND USES THEREOF
    Publication number: 20220289857
    Abstract: An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.
    Type: Application
    Filed: December 19, 2019
    Publication date: September 15, 2022
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Aihua SONG, Andrew John MCKNIGHT, Rachel Soloff NUGENT, John Lorca LAUDENSLAGER, Giuseppe DESTITO, Sarah Sunrise BUBECK, Shinya OGAWA, Yuji YAMAZAKI, David MILLS, Aruna BITRA, Dirk Michael ZAJONC
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
    Publication number: 20210388095
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 16, 2021
    Applicant: AnaptysBio, Inc.
    Inventors: Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
  • IL-36 ANTIBODIES AND USES THEREOF
    Publication number: 20210380675
    Abstract: An antibody or antigen binding fragment thereof that binds to an IL-36, wherein the antibody or antigen binding fragment thereof binds to both IL-36? and IL-36?, and wherein the antibody is an antagonist of both IL-36? and IL-36?.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 9, 2021
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Kacey Layn SACHEN, Andrew John MCKNIGHT, Rachel Soloff NUGENT, John Lorca LAUDENSLAGER, Giuseppe DESTITO, Dirk Michael ZAJONC, Aruna BITRA, Takenao YAMADA
  • Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)
    Patent number: 11130814
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: September 28, 2021
    Assignee: AnaptysBio, Inc.
    Inventors: Peter Bowers, Andrew John McKnight, David J. King, Marco Londei
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33)
    Publication number: 20210040198
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Applicant: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)
    Patent number: 10836820
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: November 17, 2020
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
    Publication number: 20200087408
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 19, 2020
    Applicant: AnaptysBio, Inc.
    Inventors: Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
  • Antibodies directed against interleukin 36 receptor (IL-36R)
    Patent number: 10526410
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 7, 2020
    Assignee: AnaptysBio, Inc.
    Inventors: Peter Bowers, Andrew John McKnight, David J. King, Marco Londei
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33)
    Publication number: 20180346562
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Application
    Filed: July 23, 2018
    Publication date: December 6, 2018
    Applicant: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Antibodies directed against interleukin-33 (IL-33) and methods of making and using
    Patent number: 10059764
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 28, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R)
    Publication number: 20180094065
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 5, 2018
    Inventors: Peter BOWERS, Andrew John MCKNIGHT, David J. KING, Marco LONDEI
  • ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33)
    Publication number: 20160333090
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 17, 2016
    Inventors: Robert A. Horlick, David J. King, Andrew John MCKNIGHT